Clinical Outcomes of Continuous Addition of Androgen Deprivation Therapy During Docetaxel Chemotherapy for Patients With Castration-Resistant Prostate Cancer.
10.22465/kjuo.2017.15.2.59
- Author:
Dong Hoon LEE
1
;
Jung Ho KIM
;
Won Ik SEO
;
Jong Kil NAM
;
Tae Nam KIM
;
Cheol Kyu OH
;
Soo Dong KIM
;
Sung Woo PARK
;
Jae Sung CHUNG
;
Sang Hyun PARK
;
Wan LEE
;
Gyung Tak SUNG
;
Moon Kee CHUNG
;
Jae Il CHUNG
Author Information
1. Department of Urology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea.
- Publication Type:Original Article
- Keywords:
Androgen deprivation therapy;
Castration-resistant prostate cancer;
Docetaxel chemotherapy
- MeSH:
Academies and Institutes;
Cohort Studies;
Disease-Free Survival;
Drug Therapy*;
Gonadotropin-Releasing Hormone;
Humans;
Medical Records;
Orchiectomy;
Prospective Studies;
Prostate*;
Prostate-Specific Antigen;
Prostatic Neoplasms*;
Retrospective Studies
- From:Korean Journal of Urological Oncology
2017;15(2):59-65
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: This study compared the oncologic results of docetaxel chemotherapy (DOC) in castration-resistant prostate cancer (CRPC) according to continuous addition of androgen deprivation therapy (ADT) during chemotherapy. MATERIALS AND METHODS: We retrospectively reviewed the medical records of 106 patients who received DOC in 6 medical institutes. Among them, 72 patients had a complete medical record: 28 patients with ADT (DOC+continuous ADT group) and 44 without ADT (DOC only group). We compared the progression-free survival of these groups after DOC. RESULTS: Docetaxel was administered an average of 28 months after primary ADT as the first treatment. A median number of 6 cycles of DOC was administered in both groups. In the DOC+continuous ADT group, orchiectomy was performed in 18 patients and luteinizing hormone-releasing hormone agonist was injected in 10 patients. During DOC treatment, prostate-specific antigen (PSA) progression-free survival was statistically different (6.0±4.75 months in DOC+continuous ADT group vs. 4.8±3.2 months in DOC only group, p=0.024), whereas radiologic progression-free survival was not statistically different (5.0±3.12 months in DOC+continuous ADT group vs. 5.0±2.79 months in DOC only group, p=0.387). CONCLUSIONS: In our cohort, continuous addition of ADT showed a significant benefit in PSA progression-free survival during DOC in CRPC patients. Further prospective studies are needed to confirm these observations.
